Cargando…

909. Reassessing Pathogens Eligible for the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) “Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection” Criteria

BACKGROUND: NHSN Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection (MBI-LCBI) includes pathogens likely to cause bloodstream infections (BSI) in some oncology patients. MBI-LCBIs are excluded from central line-associated BSI (CLABSI) reporting to the Centers for Medicare & Medica...

Descripción completa

Detalles Bibliográficos
Autores principales: Chea, Nora, Magill, Shelley, Benin, Andrea L, Allen-Bridson, Katherine, Dudeck, Margaret, Patel, Prachi, Thomson, Nicola D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777062/
http://dx.doi.org/10.1093/ofid/ofaa439.1097
_version_ 1783630818432778240
author Chea, Nora
Magill, Shelley
Benin, Andrea L
Allen-Bridson, Katherine
Dudeck, Margaret
Patel, Prachi
Thomson, Nicola D
author_facet Chea, Nora
Magill, Shelley
Benin, Andrea L
Allen-Bridson, Katherine
Dudeck, Margaret
Patel, Prachi
Thomson, Nicola D
author_sort Chea, Nora
collection PubMed
description BACKGROUND: NHSN Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection (MBI-LCBI) includes pathogens likely to cause bloodstream infections (BSI) in some oncology patients. MBI-LCBIs are excluded from central line-associated BSI (CLABSI) reporting to the Centers for Medicare & Medicaid Services. NHSN users have requested other pathogens be added to MBI-LCBI. To make decision, we compared CLABSI pathogen distributions in three NHSN patient location groups. METHODS: We analyzed CLABSI data from hospitals conducting surveillance for ≥ 1 month from January 2014–December 2018 in ≥ 1 MBI high-risk location (leukemia, lymphoma, and adult and pediatric hematopoietic stem cell transplant wards). We compared CLABSI pathogen distributions and rates in MBI high-risk locations to medium-risk (solid tumor, adult and pediatric general hematology-oncology wards) and low-risk locations (adult and pediatric medical, surgical, and medical-surgical wards), and used χ2 tests to compare percentages with statistical significance at P ≤ 0.05. RESULTS: Overall, 122 hospitals reported 23,578 CLABSIs and 12,961,921 central line (CL)-days (1.81 CLABSIs per 1,000 CL-days) (Table). Percentages of CLABSIs due to three MBI-LCBI pathogens (E. coli, E. faecium, Viridans streptococci) were significantly higher in high- versus low-risk locations, while for other MBI-LCBI pathogens (K. pneumoniae/oxytoca, E. faecalis, Candida spp., Enterobacter spp.) percentages were significantly lower in high-risk locations (Figure). For pathogens not currently in MBI-LCBI, coagulase-negative staphylococci caused similar percentages of CLABSIs across locations, S. aureus caused a significantly higher percentage of CLABSIs in low-risk locations, while PA caused a significantly higher percentage of CLABSIs in high-risk locations. Table CLABSIs attributed to MBI high-risk, medium-risk, and low-risk locations, NHSN, 2014–2018 [Image: see text] Figure Percentages of top 10 pathogen-specific CLABSIs in MBI high-risk, medium-risk, and low-risk locations, NHSN, 2014–2018 [Image: see text] CONCLUSION: Differences in percentages of CLABSIs due to selected pathogens between MBI high-risk and low-risk locations are evident in NHSN data. Lower percentages of Klebsiella and Candida spp. in high-risk locations might be partially due to antimicrobial prophylaxis in oncology patients. Although PA caused a significantly higher percentage of CLABSIs in high-risk locations, the absolute difference was modest. Additional analyses are needed. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7777062
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77770622021-01-07 909. Reassessing Pathogens Eligible for the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) “Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection” Criteria Chea, Nora Magill, Shelley Benin, Andrea L Allen-Bridson, Katherine Dudeck, Margaret Patel, Prachi Thomson, Nicola D Open Forum Infect Dis Poster Abstracts BACKGROUND: NHSN Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection (MBI-LCBI) includes pathogens likely to cause bloodstream infections (BSI) in some oncology patients. MBI-LCBIs are excluded from central line-associated BSI (CLABSI) reporting to the Centers for Medicare & Medicaid Services. NHSN users have requested other pathogens be added to MBI-LCBI. To make decision, we compared CLABSI pathogen distributions in three NHSN patient location groups. METHODS: We analyzed CLABSI data from hospitals conducting surveillance for ≥ 1 month from January 2014–December 2018 in ≥ 1 MBI high-risk location (leukemia, lymphoma, and adult and pediatric hematopoietic stem cell transplant wards). We compared CLABSI pathogen distributions and rates in MBI high-risk locations to medium-risk (solid tumor, adult and pediatric general hematology-oncology wards) and low-risk locations (adult and pediatric medical, surgical, and medical-surgical wards), and used χ2 tests to compare percentages with statistical significance at P ≤ 0.05. RESULTS: Overall, 122 hospitals reported 23,578 CLABSIs and 12,961,921 central line (CL)-days (1.81 CLABSIs per 1,000 CL-days) (Table). Percentages of CLABSIs due to three MBI-LCBI pathogens (E. coli, E. faecium, Viridans streptococci) were significantly higher in high- versus low-risk locations, while for other MBI-LCBI pathogens (K. pneumoniae/oxytoca, E. faecalis, Candida spp., Enterobacter spp.) percentages were significantly lower in high-risk locations (Figure). For pathogens not currently in MBI-LCBI, coagulase-negative staphylococci caused similar percentages of CLABSIs across locations, S. aureus caused a significantly higher percentage of CLABSIs in low-risk locations, while PA caused a significantly higher percentage of CLABSIs in high-risk locations. Table CLABSIs attributed to MBI high-risk, medium-risk, and low-risk locations, NHSN, 2014–2018 [Image: see text] Figure Percentages of top 10 pathogen-specific CLABSIs in MBI high-risk, medium-risk, and low-risk locations, NHSN, 2014–2018 [Image: see text] CONCLUSION: Differences in percentages of CLABSIs due to selected pathogens between MBI high-risk and low-risk locations are evident in NHSN data. Lower percentages of Klebsiella and Candida spp. in high-risk locations might be partially due to antimicrobial prophylaxis in oncology patients. Although PA caused a significantly higher percentage of CLABSIs in high-risk locations, the absolute difference was modest. Additional analyses are needed. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7777062/ http://dx.doi.org/10.1093/ofid/ofaa439.1097 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Chea, Nora
Magill, Shelley
Benin, Andrea L
Allen-Bridson, Katherine
Dudeck, Margaret
Patel, Prachi
Thomson, Nicola D
909. Reassessing Pathogens Eligible for the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) “Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection” Criteria
title 909. Reassessing Pathogens Eligible for the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) “Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection” Criteria
title_full 909. Reassessing Pathogens Eligible for the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) “Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection” Criteria
title_fullStr 909. Reassessing Pathogens Eligible for the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) “Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection” Criteria
title_full_unstemmed 909. Reassessing Pathogens Eligible for the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) “Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection” Criteria
title_short 909. Reassessing Pathogens Eligible for the Centers for Disease Control and Prevention’s (CDC’s) National Healthcare Safety Network (NHSN) “Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infection” Criteria
title_sort 909. reassessing pathogens eligible for the centers for disease control and prevention’s (cdc’s) national healthcare safety network (nhsn) “mucosal barrier injury-laboratory confirmed bloodstream infection” criteria
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777062/
http://dx.doi.org/10.1093/ofid/ofaa439.1097
work_keys_str_mv AT cheanora 909reassessingpathogenseligibleforthecentersfordiseasecontrolandpreventionscdcsnationalhealthcaresafetynetworknhsnmucosalbarrierinjurylaboratoryconfirmedbloodstreaminfectioncriteria
AT magillshelley 909reassessingpathogenseligibleforthecentersfordiseasecontrolandpreventionscdcsnationalhealthcaresafetynetworknhsnmucosalbarrierinjurylaboratoryconfirmedbloodstreaminfectioncriteria
AT beninandreal 909reassessingpathogenseligibleforthecentersfordiseasecontrolandpreventionscdcsnationalhealthcaresafetynetworknhsnmucosalbarrierinjurylaboratoryconfirmedbloodstreaminfectioncriteria
AT allenbridsonkatherine 909reassessingpathogenseligibleforthecentersfordiseasecontrolandpreventionscdcsnationalhealthcaresafetynetworknhsnmucosalbarrierinjurylaboratoryconfirmedbloodstreaminfectioncriteria
AT dudeckmargaret 909reassessingpathogenseligibleforthecentersfordiseasecontrolandpreventionscdcsnationalhealthcaresafetynetworknhsnmucosalbarrierinjurylaboratoryconfirmedbloodstreaminfectioncriteria
AT patelprachi 909reassessingpathogenseligibleforthecentersfordiseasecontrolandpreventionscdcsnationalhealthcaresafetynetworknhsnmucosalbarrierinjurylaboratoryconfirmedbloodstreaminfectioncriteria
AT thomsonnicolad 909reassessingpathogenseligibleforthecentersfordiseasecontrolandpreventionscdcsnationalhealthcaresafetynetworknhsnmucosalbarrierinjurylaboratoryconfirmedbloodstreaminfectioncriteria